Lilly, a leading medicine company, has announced that its oral GLP-1 medication orforglipron delivered significant weight loss results in adults with obesity, achieving an average of up to 27.3 pounds in the first two pivotal Phase 3 trials.
The ATTAIN-1 trial demonstrated orforglipron’s efficacy and safety profile, showing superior body weight reduction compared to placebo at 72 weeks. Participants taking the highest dose of orforglipron lost an average of 27.3 pounds (12.4%) during this period, with 59.6% losing at least 10% of their body weight and 39.6% losing at least 15%.
Orforglipron’s effects went beyond weight loss, also reducing known markers of cardiovascular risk such as non-HDL cholesterol, triglycerides, and systolic blood pressure in pooled analyses across all doses. In a pre-specified exploratory analysis, the highest dose of orforglipron reduced high-sensitivity C-reactive protein (hsCRP) levels by 47.7%.
The company is now on track to submit orforglipron for global regulatory approval by year-end and will make substantial investments to meet anticipated demand at launch.
Lilly’s efforts aim to address the pressing global health challenge of obesity, which impacts over one billion people worldwide and drives chronic disease burden. With this milestone, Lilly continues its pursuit of innovative solutions to tackle significant health challenges, including redefining diabetes care, treating obesity, advancing Alzheimer’s disease research, and developing treatments for debilitating immune system disorders.
The ATTAIN Phase 3 global clinical development program for orforglipron has enrolled over 4,500 participants across two global registration trials. Lilly is committed to delivering accessible and affordable medicines, working with diverse populations to reflect the complexities of real-world healthcare.
Source: https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-delivers-weight-loss-average-273